Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 10/20 | 0.68 |
| ▸ | PRSS1 | P07477 | 6/20 | 0.54 |
| ▸ | MRGPRX1 | Q96LB2 | 4/20 | 0.54 |
| ▸ | F2 | P00734 | 2/20 | 0.54 |
| ▸ | F10 | P00742 | 1/20 | 0.54 |
| ▸ | F7 | P08709 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | PLG | P00747 | 1/20 | 0.46 |
| ▸ | PLAT | P00750 | 1/20 | 0.46 |
| ▸ | KLK1 | P06870 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7338672 | 0.81 | PLAU (1.00) | PLAUPRSS1MRGPRX1F2PLG | |
| SCHEMBL7343484 | 0.74 | PLAU (0.70) | PLAUPRSS1F2PLGPLAT | |
| SCHEMBL7369251 | 0.74 | PLAU (0.71) | PLAUPRSS1MRGPRX1F2F10 | |
| Trifluoroacetic Acid SCHEMBL7856857 | 0.74 | PLAU (0.83) | PLAUPRSS1F2PLGPLAT | |
| Hydrochloric Acid SCHEMBL7335552 | 0.73 | PLAU (0.69) | PLAUPRSS1MRGPRX1F2F10 | |
| SCHEMBL7333503 | 0.72 | PLAU (0.79) | PLAUPRSS1F2PLGPLAT | |
| SCHEMBL7337592 | 0.72 | PLAU (0.60) | PLAUPRSS1F2PLGPLAT | |
| Trifluoroacetic Acid SCHEMBL7336904 | 0.71 | PLAU (0.59) | PLAUPRSS1F2PLGPLAT | |
| SCHEMBL5759617 | 0.71 | PRSS1 (0.70) | PRSS1MRGPRX1F2F10F7 | |
| Trifluoroacetic Acid SCHEMBL7342930 | 0.69 | PLAU (0.61) | PLAUPRSS1F2PLGPLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010049374-A1 | Urokinase inhibitors | STEELE ANDREW W (US) | 2001-12-06 | — | — | US | claimed |
| EP-1000018-A2 | UROKINASE INHIBITORS | Abbott Laboratories (US) | 2000-05-17 | — | — | EP | claimed |
| WO-1999005096-A2 | UROKINASE INHIBITORS | ABBOTT LABORATORIES (US) | 1999-02-04 | — | — | WO | claimed |
| US-20010049374-A1 | Urokinase inhibitors | STEELE ANDREW W (US) | 2001-12-06 | — | — | US | disclosed |
| US-6284796-B1 | NAPHTHAMIDINE COMPOUNDS | ABBOTT LABORATORIES | 2001-09-04 | — | — | US | disclosed |
| US-6258822-B1 | ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS | ABBOTT LABORATORIES | 2001-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049374-A1 | Urokinase inhibitors | SERPINE1, PLAU, SERPINB1 | PLAU 2/4885PRSS1 16/4885MRGPRX1 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.